CAMBRIDGE, Mass., Aug. 25, 2022 -- Aktis Oncology, a biotechnology company discovering and developing novel classes of targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced...
BrainCells Gets $8M In First Part Of Committed $17.7M Series A
News | 07. 15. 2005
BrainCells Inc., a neuroscience-focused drug discovery and development company targeting therapies for depression, related neuropsychiatric disorders and other central nervous system diseases, has closed on commitments of $17.7 million for its Series A round.